What is Complete Genomics?
Complete Genomics operates as a specialized research and development center of excellence, focusing on the complex field of human genome sequencing. By providing comprehensive, high-quality genomic data, the company serves as a vital partner for researchers and clinicians aiming to decode the genetic basis of disease. Its market position is defined by its ability to deliver scalable, cost-effective sequencing solutions that address the growing demand for precision medicine and personalized healthcare. Through its proprietary sequencing platforms, the company has established a reputation for technical precision and operational reliability, positioning itself at the forefront of the digital biology revolution.
How much funding has Complete Genomics raised?
Complete Genomics has raised a total of $197M across 7 funding rounds:
Series A
$6M
Series B
$12M
Series C
$26.5M
Debt
$14.5M
Series D
$45M
Series E
$39M
Stock Offering
$54M
Series A (2006): $6M with participation from Enterprise Partners Venture Capital and OVP Venture Partners
Series B (2007): $12M, investors not publicly disclosed
Series C (2008): $26.5M supported by Highland Crusader Offshore Partners L.P., OVP Venture Partners VI L.P., Enterprise Partners VI L.P., and Prospect Venture Partners III L.P.
Debt (2009): $14.5M, investors not publicly disclosed
Series D (2009): $45M backed by Prospect Venture Partners, OrbiMed, OVP Venture Partners, Essex Woodlands Health Ventures, and Highland Capital Partners
Series E (2010): $39M with participation from Prospect Venture Partners, OrbiMed, OVP Venture Partners, Sands Capital, Essex Woodlands Health Ventures, and Highland Capital Partners
Stock Issuance/Offering (2010): $54M, investors not publicly disclosed
Key Investors in Complete Genomics
Prospect Venture Partners
A prominent life sciences venture capital firm focused on building exceptional biomedical companies, supporting innovation from seed to growth stage.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics.
OVP Venture Partners
A venture capital firm with a focus on high-growth technology markets, including digital biology and information technology in the Pacific Northwest.
What's next for Complete Genomics?
Looking ahead, the strategic deployment of the $54M capital is expected to accelerate the commercialization of next-generation sequencing platforms and enhance the company's competitive advantage in the global market. As the firm moves beyond its initial development phase, the focus will likely shift toward expanding its diagnostic service offerings and deepening its integration into clinical workflows. By maintaining strong relationships with its core investor base, Complete Genomics is well-positioned to navigate the evolving regulatory environment and capitalize on the increasing adoption of genomic data in therapeutic development and patient care, ensuring long-term sustainability and market leadership.
See full Complete Genomics company page
